Sorafenib rechallenge in patients with metastatic renal cell carcinoma

BJU International
Masahiro NozawaHirotsugu Uemura

Abstract

What's known on the subject? and What does the study add? Targeted agents with a similar or different target molecule are often used sequentially in the treatment of metastatic RCC. Two tyrosine kinase inhibitors, sorafenib and sunitinib, have been reported to show little cross-resistance, when used sequentially. In addition, a recent report showed that sunitinib rechallenge could potentially benefit selected patients. This case series shows that patients once refractory to sorafenib could regain disease control on rechallenge with sorafenib during sequential treatment. Outcomes of the sorafenib rechallenge were not significantly affected by the response to the initial sorafenib treatment or by the duration of intervening treatments between first sorafenib and rechallenge. To investigate clinical outcomes of sorafenib rechallenge during sequential therapy for patients with metastatic renal cell carcinoma (RCC). Patients with metastatic RCC who received sorafenib rechallenge after failed treatment first with sorafenib and subsequently with other agents, were retrospectively reviewed for patient characteristics, best response, progression-free survival (PFS), and adverse events (AEs). Of the 14 patients who received sorafenib rec...Continue Reading

References

Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
May 12, 2007·European Urology·Paul C M S Verhagen
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Dec 18, 2007·Lancet·Tammy F ChuMing Hui Chen
Dec 4, 2008·Cancer·Arkadiusz Z DudekCezary Szczylik
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jan 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierRonald M Bukowski
Apr 30, 2009·Cancer·Bernard EscudierKarim Fizazi
May 19, 2009·The Journal of Urology·M P SablinB Escudier
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cora N SternbergRobert E Hawkins
Apr 20, 2010·Critical Reviews in Oncology/hematology·Joaquim BellmuntDavid Quinn
Jul 27, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Thomas E HutsonUNKNOWN Sorafenib TARGET Clinical Trial Group
Aug 14, 2010·Critical Reviews in Oncology/hematology·Thomas E HutsonCora N Sternberg
Nov 26, 2010·Cancer·Ivan N ZamaBrian I Rini

❮ Previous
Next ❯

Citations

Sep 4, 2013·Nature Reviews. Clinical Oncology·Elizabeth A KuczynskiRobert S Kerbel
Sep 7, 2014·BMC Urology·Anna M CzarneckaCezary Szczylik
May 8, 2014·British Journal of Cancer·C PortaV Grünwald
Dec 3, 2015·Expert Opinion on Pharmacotherapy·Camillo PortaChiara Paglino
Nov 26, 2014·International Journal of Urology : Official Journal of the Japanese Urological Association·Yong Hyun ParkSang Eun Lee
Apr 10, 2016·Journal of the National Cancer Institute·Elizabeth A KuczynskiRobert S Kerbel
Dec 3, 2014·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Johannes C van der MijnHenk M Verheul
Feb 22, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rahul AggarwalPamela N Munster
Mar 3, 2017·International Journal of Urology : Official Journal of the Japanese Urological Association·Sumanta K PalNicholas J Vogelzang
May 27, 2014·American Society of Clinical Oncology Educational Book·Manuela Schmidinger
Jul 7, 2015·Current Opinion in Urology·Stéphane Oudard, Yann Vano
Oct 18, 2016·Oncology Reports·Jianwei ZhuQifeng Guo
Jan 5, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·D ViñalE Espinosa
Nov 1, 2017·Case Reports in Oncological Medicine·Ryo KasaharaKazuki Kobayashi
Apr 25, 2015·Cancer Research·Elizabeth A KuczynskiRobert S Kerbel
Mar 16, 2021·International Journal of Urology : Official Journal of the Japanese Urological Association·Kotaro SuzukiMasato Fujisawa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.